Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in New Jersey: - Summit Medical Group Cancer Center ( Site 0007) — Florham Park, New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016) — Hackensack, New Jersey
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in New Jersey: - Rutgers Biomedical and Health Sciences — New Brunswick, New Jersey
Phase 2, Phase 3 Recruiting Industry
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Sites in New Jersey: - John Theurer Cancer Center / Hackensack University — Hackensack, New Jersey
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Saint Peter's University Hospital — New Brunswick, New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
- Newark Beth Israel Medical Center — Newark, New Jersey
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
- Saint Joseph's Regional Medical Center — Paterson, New Jersey
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
- Saint Joseph's Regional Medical Center — Paterson, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in New Jersey: - Hunterdon Hematology Oncology — Flemington, New Jersey
- Summit Medical Group — Florham Park, New Jersey
Phase 2 Recruiting Industry
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in New Jersey: - John Theurer Cancer Center - Hackensack Meridian Health — Hackensack, New Jersey
- Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey ( Site 1008) — New Brunswick, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transform…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04728893
Sites in New Jersey: - Astera Cancer Care ( Site 2732) — East Brunswick, New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704) — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Sponsor: AstraZeneca
NCT ID: NCT06542250
Sites in New Jersey: - Research Site — Hackensack, New Jersey
Phase 2 Recruiting Industry
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\]…
Sponsor: Bio-Path Holdings, Inc.
NCT ID: NCT02781883
Sites in New Jersey: - New Jersey Hematology Oncology Associates — Brick, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer a…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07400029
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a trea…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03824483
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether a 3-drug combination of ivosidenib, azacitidine, and venetoclax followed by maintenance therapy with ivosidenib alone is an effective treatment approach for people with newly diagnos…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07392242
Sites in New Jersey: - Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infe…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06698003
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (All protocol activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out if azacitidine and venetoclax are an effective treatment approach to get rid of or lower measurable residual disease (MRD) in people with acute myeloid leukemia (AML) who have received standard chem…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06773208
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Industry
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an …
Sponsor: Orca Biosystems, Inc.
NCT ID: NCT07216443
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 1 Recruiting Industry
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may sto…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06484062
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1 Recruiting Industry
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Sponsor: Schrödinger, Inc.
NCT ID: NCT05544019
Sites in New Jersey: - Regional Cancer Care Associates — Hackensack, New Jersey
Phase 1 Recruiting Industry
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.
Sponsor: Orca Biosystems, Inc.
NCT ID: NCT03802695
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidin…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06419634
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey